{Reference Type}: Journal Article
{Title}: Pharmacotherapies for multidrug-resistant gram-positive infections: current options and beyond.
{Author}: Leone S;Pezone I;Pisaturo M;McCaffery E;Alfieri A;Fiore M;
{Journal}: Expert Opin Pharmacother
{Volume}: 25
{Issue}: 8
{Year}: 2024 Jun 13
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2367003
{Abstract}: <B>UNASSIGNED: </B>Infections due to multidrug-resistant organisms (MDRO) are a serious concern for public health with high morbidity and mortality. Though many antibiotics have been introduced to manage these infections, there are remaining concerns regarding the optimal management of Gram-positive MDROs.<BR><B>UNASSIGNED: </B>A literature search on the PubMed/Medline database was conducted. We applied no language and time limits for the search strategy. In this narrative review, we discuss the current options for managing Gram-positive MDROs as well as non-traditional antibacterial agents in development.<BR><B>UNASSIGNED: </B>Despite their introduction more than 70 years ago, glycopeptides are still the cornerstone in treating Gram-positive infections: all registrative studies of new antibiotics have glycopeptides as control; these studies are designed as not inferior studies, therefore it is almost impossible to give recommendations other than the use of glycopeptides in the treatment of Gram-positive infections. The best evidence on treatments different from glycopeptides comes from post-hoc analysis and meta-analysis. Non-traditional antibacterial agents are being studied to aid in short and effective antibiotic therapies. The use of non-traditional antibacterial agents is not restricted to replacing traditional antibacterial agents with alternative therapies; instead, they should be used in combination with antibiotic therapies.